Tag - DXR


Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.